Methodology, Tools, and Computation
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development
Ana Ruiz-Garcia, Paul Baverel, Dean Bottino, Michael Dolton, Yan Feng, Ignacio González-García, Jaeyeon Kim, Seth Robey, Indrajeet Singh, David Turner, Shu-Pei Wu, Donghua Yin, Di Zhou, Hao Zhu, Peter Bonate. J Pharmacokinet Pharmacodyn. March, 4 2023
An Introduction to Bayesian Estimation in NONMEM
Tim Waterhouse. Presented at 12th Annual Indiana Clinical and Translational Sciences Institute (CTSI) Symposium on Disease and Therapeutic Response Modeling. February 23, 2023.
A Showcase of Open-Source Tools for Scalable, Reproducible Pharmacometrics Workflows
Sam Callisto, Tim Waterhouse. Presented at 12th Annual Indiana Clinical and Translational Sciences Institute (CTSI) Symposium on Disease and Therapeutic Response Modeling. February 23, 2023.
Variable or variate? A conundrum in pharmacometrics exposure–response models
Ana-Marija Grisic, Karthik Venkatakrishnan, Jonathan French, Akash Khandelwal. CPT Pharmacometrics Syst Pharmacol. December, 20 2022. doi:10.1002/psp4.12905
A Population Pharmacokinetic-Pharmacodynamic Model Evaluating Efficacy of Nalbuphine Extended-Release in Patients with Prurigo Nodularis
Rena Eudy-Byrne, Matthew Riggs, Amale Hawi, Thomas Sciascia, Shashank Rohatagi. Br J Clin Pharmacol. 2023. doi:10.1111/bcp.15663
Bayesian PBPK Modeling using R/Stan/Torsten and Julia/SciML/Turing.jl
Ahmed Elmokadem, Yi Zhang, Timothy Knab, William R. Gillespie. CPT Pharmacometrics Syst Pharmacol. January, 20 2023. doi:10.1002/psp4.12926
Shrinkage in Population PK/PKPD Analysis
Sonoko Kawakatsu. Virtual presentation for Children’s Hospital of Philadelphia and Cincinnati’s Children’s Hospital. 13 December 2022.
Emerging use of real-world data to address data gaps in clinical pharmacology: Opportunities and challenges
Simon Dagenais, Marc Gastonguay, Abie Ekangaki. Hot topic presented at 2022 AAPS PharmSci360. 17 October 2022.
An Introduction to Causal Inference for Pharmacometricians
James Rogers, Hugo Maas, Alejandro Perez Pitarch. CPT Pharmacometrics Syst Pharmacol. November, 16 2022. doi:10.1002/psp4.12894
Disease Trajectory of SLE Clinical Endpoints and Covariates Affecting Disease Severity and Probability of Response: Analysis of Pooled Patient-Level Placebo (Standard-of-Care) Data to Enable Model-Informed Drug Development
Kosalaram Goteti, Jonathan French, Ramon Garcia, Ying Li, Florence Casset-Semanaz, Aida Aydemir, Robert Townsend, Cristina Vazquez Mateo, Matthew Studham, Oliver Guenther, Amy Kao, Marc Gastonguay, Pascal Girard, Lisa Benincosa, Karthik Venkatakrishnan. CPT Pharmacometrics Syst Pharmacol. November, 9 2022. doi:10.1002/psp4.12888
Application of Model-Based Meta-Analysis to Set Benchmarks for New Treatments of Systemic Lupus Erythematosus
Kosalaram Goteti, Ramon Garcia, William Gillespie, Jonathan French, Lena Klopp-Schulze, Ying Li, Cristina Vazquez Mateo, Sanjeev Roy, Oliver Guenther, Lisa Benincosa, Karthik Venkatakrishnan. Poster presented at 2022 American Conference on Pharmacometrics (ACoP13). 30 October – November 2 2022. Poster T-075
A showcase of open-source tools for scalable, reproducible PMx workflows
Kyle Baron, Sam Callisto, Seth Green, Matthew Riggs. A showcase of open-source tools for scalable, reproducible PMx workflows. Pre Meeting Workshop presented at 2022 American Conference on Pharmacometrics (ACoP13). 30 October 2022.
Bayesian PBPK Modeling using R/Stan/Torsten and Julia/SciML/Turing.jl
Ahmed Elmokadem, Yi Zhang, Tim Knab, Eric Jordie, William R. Gillespie. Poster presented at 2022 American Conference on Pharmacometrics (ACoP13). 30 October – November 2 2022. Poster W-074
Analysis Planning and Interpretation Using Causal Directed Acyclic Graphs: A Case Study in Oncology
James A. Rogers, Hugo Maas, Alejandro Peréz. Poster presented at 2022 American Conference on Pharmacometrics (ACoP13). 30 October – November 2 2022. Poster T-022
A Suite of Open-Source Tools to Guide Efficient Pharmacometric Analyses
Katherine Kay, Kyle Baron, Seth Green, Samuel Callisto, Curtis Johnston, Kyle Barrett, Devin Pastoor, Jim Rogers, Ana Ruiz-Garcia, Tim Waterhouse, Matthew Wiens, Matthew Riggs. Poster presented at 2022 American Conference on Pharmacometrics (ACoP13). 30 October – November 2 2022. Poster M-062
Using Graphical Models and Causal Thinking to Inform Pharmacometric Modeling
Jonathan French. Presented at Bayes 2022. 12 – 14 October 2022.
Using Quarto to showcase an ecosystem of open-source R packages for Pharmacometrics
Seth Green. Presented at R/Medicine 2022. 26 August 2022.
Landscape analysis for a neonatal disease progression model of bronchopulmonary dysplasia: Leveraging clinical trial experience and real-world data
Jeffrey S. Barrett, Megan Cala Pane, Timothy Knab, William Roddy, Jack Beusmans, Eric Jordie, Kanwaljit Singh, Jonathan Michael Davis, Klaus Romero, Michael Padula, Bernard Thebaud, Mark Turner. Front. Pharmacol. 2022 October 12. doi: 10.3389/fphar.2022.988974
QSP to Link Learn/Confirm with Expand/Understand in Model-Informed Drug Development Integrating Evidence Across Theory and Observation
Matthew Riggs. Presented at the University of Buffalo QSP Symposium 2022. 28 July 2022
QSP to Link Learn:Confirm with Expand:Understand in Model-Informed Drug Development
Flexible and efficient Bayesian pharmacometrics modeling using Stan and Torsten, Part I
Charles C. Margossian, Yi Zhang, William R. Gillespie. Flexible and efficient Bayesian pharmacometrics modeling using Stan and Torsten, Part I. CPT Pharmacometrics Syst Pharmacol. 2022 May 15. doi: 10.1002/psp4.12812. Epub ahead of print. PMID: 35570331.
Pharmacometrics Golems: Exposure-Response Models in Oncology
Modeling Reaction Time Distributions Increases the Statistical Power of Cognition Testing
Seth C. Hopkins, Sean D. Wilson, Ajay Ogirala, Gabriel Stellman, Snezana M. Milanovic, Steven T. Szabo, James A. Rogers, Chris J. Edgar, Kenneth S. Koblan. Poster presented at 2021 American College of Neuropsychopharmacology. 5-8 December 2021.
I’m a Bayesian and I’m OK: Or How I Learned to Stop Worrying and Love Variability and Uncertainty
William R. Gillespie. The Lewis B. Sheiner Lecturer Award slides presented at International Society of Pharmacometrics. November 2021.
A Torsten case study: Evaluating the benefits of cross-chain communication during the warmup phase of Hamiltonian Monte Carlo (HMC) simulation
Yi Zhang and William R. Gillespie. Poster presented at 2021 American Conference on Pharmacometrics (ACoP12) virtual meeting. 8-12 November 2021. Poster PIIIB-028
Development and validation of open-source pharmacometrics software using an iterative software development life cycle methodology: the pmtables R package for submission-ready table generation
Kyle T. Baron, Devin Pastoor, Anna Nevison, Katherine Kay, Marc R. Gastonguay. Poster presented at Population Approach Group Europe Annual Meeting; 2-3 and 6-7 September 2021. Poster III-02.
Torsten: Stan functions for pharmacometric applications – Improvements and new R interface workflow
Yi Zhang and William R. Gillespie. Poster presented at Population Approach Group Europe Annual Meeting; 2-3 and 6-7 September 2021. Poster I-61.
Decision making in drug development: An opportunity for model-based knowledge integration and scenario evaluation.
Seminar presented by Marc R. Gastonguay, Ph.D., at the FDA’s Model Informed Drug Development (MIDD) Education Series, April 26, 2021 (virtual).
Opportunities at the Intersection of Pharmacometrics and Health Economics for Insightful Drug Development Decision Making
Marc Gastonguay, Jing Liu, Jean Lachaine, Anna G. Kondic, and Daniel Polhamus. Presented at the American Society for Clinical Pharmacology (ASCPT) annual meeting, March 15, 2021.
Theory, Empiricism, Certain Random Events, and a Vision for the Continued Growth of Pharmacometrics
Presentation by Marc Gastonguay for the ASCPT Sheiner-Beal Award during the American Society for Clinical Pharmacology (ASCPT) annual meeting, March 11, 2021.
Complex genetic dependencies among growth and neurological phenotypes in healthy children: Towards deciphering developmental mechanisms
Uechi L, Jalali M, Wilbur JD, French JL, Jumbe NL, Meaney MJ, Gluckman PD, Karnani N, Sakhanenko NA, Galas DJ; GUSTO study group. PLoS One. 2020 Dec 3;15(12):e0242684. doi: 10.1371/journal.pone.0242684.
Speed up population Bayesian inference by combining cross-chain warmup and within-chain parallelization
Yi Zhang, William R. Gillespie, Ben Bales, Aki Vehtari. Poster presented at 2020 American Conference on Pharmacometrics (ACoP11) virtual meeting. 11 November 2020.
Improving strategic decision-making with early prediction of survival outcomes in oncology clinical trials
Presentation by Jonathan L. French, Sc.D. at 2020 American Conference on Pharmacometrics (ACoP11) virtual meeting. 11 November 2020.
Markov models at the intersection of pharmacometrics and health economics
Presentation by Marc Gastonguay, Ph.D. at 2020 American Conference on Pharmacometrics (ACoP11) virtual meeting. 11 November 2020.
Quantification of the Impact of Partition Coefficient Prediction Methods on PBPK Model Output Using a Standardized Tissue Composition
Utsey, Kiersten, Madeleine S. Gastonguay, Sean Russell, Reed Freling, Matthew M. Riggs, and Ahmed Elmokadem. 2020. Drug Metabolism and Disposition: The Biological Fate of Chemicals, July. https://doi.org/10.1124/dmd.120.090498.
The confluence of Statistical and Pharmacometric Approaches for Benefit Risk Analysis: a case study using Bayesian joint models for safety and efficacy
Presented by Jonathan French, Sc.D., at the American Conference on Pharmacometrics (ACoP10) during the tutorial: The Role of Pharmacometrics in Advancing Quantitative Benefit-Risk Assessments for Drug Review and Approval. 24 Oct 2019
Transparent, Open and Reproducible PBPK and QSP Modeling and Simulation Using an R-Based Framework
Presented by Ahmed Elmokadem, Ph.D at the 9th Annual CTSI Disease and Therapeutic Response Modeling and Simulation Symposium at Indiana University School of Medicine on November 12, 2019. Event details can be found here.
Considerations and Future Directions for the Development of Open-Source, Public License, Pharmacometric Software
Presented by Marc Gastonguay, Ph.D. at ACCP Annual Meeting September 17, 2019.
Population and ODE-based models using Stan and Torsten
Margossian C, Zhang Y. Workshop presented at StanCon 2019. Cambridge UK. 20-21 August 2019.
Solving the Package Management Puzzle
Pastoor, Devin. Presentation at R/Pharma. Cambridge, MA. 22 Aug 2019.
Prediction of maternal-fetal exposures of CYP450-metabolized drugs using physiologic pharmacokinetic modeling implemented in R and mrgsolve
Gastonguay, Madeleine. Presentation at R/Pharma. Cambridge, MA. 23 Aug 2019.
Development of an open-source physiologically-based pharmacokinetic model to predict maternal-fetal exposures of CYP450-metabolized drugs
Gastonguay MS, Russell S, Freling R, Riggs M, Kay K, Utsey K, Elmokadem A.
Poster presented at 2019 American Society for Clinical Pharmacology & Therapeutics (ASCPT). Washington DC. 14 March 2019.
Poster presented at ISoP Regional QSP Day 2019. Princeton, NJ. 16 July 2019.
Torsten: Stan functions for pharmacometric applications. New functionality including within chain parallel computation.
Zhang Y, Gillespie W. Poster presented at 2019 Population Approach Group in Europe (PAGE). Stockholm, Sweden. 13 June 2019. Abstract IV-29.
Causa Nostra: the potentially legitimate business of drawing causal inferences from observational data
Rogers JA. CPT Pharmacometrics Syst Pharmacol [Internet]. 2019 Feb 14; Available from: http://dx.doi.org/10.1002/psp4.12395
Causa Nostra: The potentially legitimate business of drawing causal inferences from observational data
Rogers JA. Presentation at 2018 American Conference on Pharmacometrics (ACoP9). San Diego, CA. 9 Oct 2018.
A physiologically-based pharmacokinetic model for Voriconazole explores differences in pharmacokinetics between adults and children
Elmokadem A. Poster presented at 2018 American Conference on Pharmacometrics (ACoP9). San Diego, CA. 9 Oct 2018. Abstract #M-003.
Evaluating the impact of estimated partition coefficients by different methods using a unified PBPK model
Elmokadem A. Lightning talk presented at International Society of Pharmacometrics New England 2018. Cambridge, MA. 12 Sep 2018.
Development of an open and general physiologically-based pharmacokinetic model to predict maternal-fetal exposures for drugs metabolized by CYP isoenzymes
Gastonguay MS. Presented at the R/Medicine 2018 Conference. New Haven, CT. 8 Sep 2018.
Bayesian inference with partial differential equations using Stan
Zhang Y, Gillespie WR, Minjie Zhu. Poster presented at StanCon. Helsinki, Finland. 30 Aug 2018.
A perspective on the state of pharmacometrics and systems pharmacology integration
Trame MN, Riggs MM, Biliouris K, Marathe D, Mettetal J, Post TM, Rizk ML, Visser SAG, Musante CJ. CPT Pharmacometrics Syst Pharmacol. doi:10.1002/psp4.12313. 21 August 2018.
R as the core technology to support modeling and simulation in pharma research, development, and post approval activities
Gastonguay MR. Lightning Talk presented at the 1st annual R/Pharma conference. Boston, MA. 16 August 2018.
Assisting pharmacometric simulation with the use of Shiny
Kang J. Lightning Talk presented at the 1st annual R/Pharma conference. Boston, MA. 16 August 2018.
Moving fast without breaking things: navigating the R ecosystem in an enterprise environment
Pastoor D. Invited Talk presented at the 1st annual R/Pharma conference. Boston, MA. 15 August 2018.
Torsten: Stan functions for pharmacometrics applications
Gillespie WR. Presented at Stan for Pharmacometrics. Paris, France. 24 July 2018.
The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome
Moore JN, Gastonguay MR, Ng CM, Adeniyi-Jones SC, Moody DE, Fang WB, Ehrlich ME, Kraft WK. Clin Pharmacol Ther. 103 (6) 1029-1037; June 2018
Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana
Vujkovic M, Bellamy SL, Zuppa AF, Gastonguay MR, Moorthy GS, Ratshaa B, Han X, Steenhoff AP, Mosepele M, Strom BL, Bisson GP, Aplenc R, Gross R. Pharmacogenomics J. doi: 10.1038/s41397-018-0028-2. Epub June 1, 2018.
A joint design for functional data with application to scheduling ultrasound scans
Park SY, Xiao L, Wilbur JD, Staicu A, Jumbe NL. Computational Statistics and Data Analysis. 122:101-114. June 2018
Bayesian data analysis using Stan/Torsten for pharmacometric applications
Gillespie WR. Presented at the Midwest Biopharmaceutical Statistics Workshop (MBSW), Indianapolis, IN, May 2018.
Modeling methods for analyzing tumor dynamic data from basket trials
Ocampo-Pelland AS, French JL. Presented at the 8th American Conference on Pharmacometrics (ACoP), Fort Lauderdale, FL, October 2017.
Post-approval decision making supported by modeling and simulation based on a variety of data sources
Gastonguay MR. Presented at the 8th American Conference on Pharmacometrics (ACoP), Fort Lauderdale, FL, October 2017.
Gaining efficiency by combining analytical and numerical methods to solve ODEs: Implementation in Stan and application to Bayesian PK/PD modeling
Margossian C and Gillespie WR. Presented at the 8th American Conference on Pharmacometrics (ACoP), Fort Lauderdale, FL, October 2017.
Points to consider when making inferences about covariates
Gastonguay MR. Presented at the 8th American Conference on Pharmacometrics (ACoP), Fort Lauderdale, FL, October 2017.
Theory, empiricism, and a vision for the continued growth of pharmacometrics
Gastonguay MR. The International Society of Pharmacometrics Lewis B. Sheiner Award Lecture presented at the 8th American Conference on Pharmacometrics (ACoP), Fort Lauderdale, FL, October 15, 2017.
A joint optimal design for functional data with application to scheduling ultrasound scans
Park SY, Xia L, Wilbur J, Staicu AM, Jumbe NL. Paper presented at: Eastern North American Region (ENAR) Spring Meeting of the International Biometric Society, March 2017, Washington, DC.
Evaluating effectiveness of case-matching for exposure-response analysis
Wilbur JD, Gupta M, Passey C, Roy A. Poster presented at Eastern North American Region (ENAR) Spring Meeting of the International Biometric Society, March 2017, Washington, DC; Abstract 57d.
Stan functions for Bayesian pharmacometric modeling
Margossian CC and Gillespie WR. Presented at the 7th American Conference on Pharmacometrics (ACoP), Bellevue, WA; October 2016.
MBMA of combined individual and aggregate data: strategies and issues
Gillespie WR. Presented at the 7th American Conference on Pharmacometrics (ACoP), Bellevue, WA; October 2016.
Bayesian pharmacometric modeling with BUGS, NONMEM, and Stan
Gillespie WR. Presented at the 7th American Conference on Pharmacometrics (ACoP), Bellevue, WA; October 2016.
Causal models with pharmacometric applications
French JL. Presented at the 7th American Conference on Pharmacometrics (ACoP), Bellevue, WA; October 2016.
Interactive simulation-based assessment of “go/no-go” decision making in Duchenne muscular dystrophy clinical trials
Hajjar J, French JL, Gastonguay MR. Presented at the 7th American Conference on Pharmacometrics (ACoP), Bellevue, WA; October 2016.
Automation of Population Pharmacokinetic-Pharmacodynamic Modeling Reports Using the RShiny Application: TFL Generator
Melhem M, Polhamus D, Lau T, Chen P, Narayanan A, Clements JD, Gibbs J, Seegan G. Presented at the 7th American Conference on Pharmacometrics (ACoP), Bellevue, WA; October 2016.
Prototype Stan functions for Bayesian pharmacometric modeling
Gillespie WR and Margossian CC. Presented at Stan for Pharmacometrics Day, Paris 22 Sep 2016.
Facilitating clinical trial simulation in Alzheimer’s disease using the CAMD IPD, literature summary level data, and the ‘adsim’ R package
Polhamus D. Presented at The Joint Statistical Meetings (JSM), August, 2016.
Optimal design for sampling functional data
Park SY, Xia L, Wilbur J, and Staicu, AM. Presented at The Joint Statistical Meetings (JSM), August 2016, Chicago, IL; Abstract 319197.
Comparisons of multiple exposure-response methodologies in oncology.
Polhamus D, French J, Chen SC, Wang B, Li C, Lu D, Girish S, Jin J, Quartino A. Presented at the Annual Meeting of the Population Approach Group in Europe (PAGE), Lisboa, June 2016.
Comparison of recursive partitioning analysis and receiver operating characteristic (ROC) analysis for patient identification
Chen SC, Riggs MM, Nueesch E, Strasak A, French J, Jin J, Girish S, Li C. Presented at the Annual Meeting of the Population Approach Group in Europe (PAGE), Lisboa, June 2016.
A case study in comparing cognitive development across populations
French JL, Racine A, van Buuren S, Haggstrom J. Presented at the Annual Meeting for the Population Approach Group in Europe (PAGE), Lisboa, June 2016.
Evaluating effectiveness of case-matching for exposure-response analysis
Wilbur JD, Gupta M, Passey C, Roy A. Presented at the Annual Meeting of the Population Approach Group in Europe (PAGE), Lisboa, June 2016.
Zika microcephaly cutoffs revisited: A study of Non-parametric methods in fetal growth
Wilbur JD, Ohuma E, Xiao L, Mouksassi S, Hafen R. Presented at the Annual Meeting of the Population Approach Group in Europe (PAGE), Lisboa, June 2016.
The role of simulation in assessing extrapolation assumptions
Gastonguay MR. Presented at the Quantitative Assessment of Assumptions to Support Extrapolation of Efficacy in Pediatrics: FDA – U Maryland CERSI Cosponsored Workshop. FDA. June 1, 2016.
Comparing the performance of four open-source methods for multiple parameter estimation in a systems pharmacology model
Eudy RJ, Riggs MM, Baron K. Presented at the Sanofi–MSISB Mount Sinai Systems Pharmacology Symposium, June 2016.
Estimation of exposure-response relationships in the presence of confounding
French JL. Presented at Trends and Innovation in Clinical Trial Statistics Conference, Durham, NC; May 2016.
Big Data: Challenges and opportunities for clinical pharmacology
Flockhart D, Bies RR, Gastonguay MR, Schwartz SL. Br J Clin Pharmacol. 2016 May;81(5):804-6.
Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for Vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data
Ocampo-Pelland AS, Gastonguay MR, French JF, Riggs MM. J Pharmacokinet Pharmacodyn. 2016 Apr;43(2):191-206.
Facilitating cardiovascular safety exposure-response modeling in early-phase clinical studies with the cardioModel package for R
Conrado DJ, Hather GJ, Chen D, Denney WS. Facilitating Cardiovascular Safety Exposure-Response Modeling in Early-Phase Clinical Studies with the cardioModel Package for R. Presented at the 6th American Conference on Pharmacometrics (ACoP), Arlington, VA, October 2015
A pharmacometrician’s perspective for utilization of big data
Gastonguay MR. Presented at the 6th American Conference on Pharmacometrics (ACoP), Arlington, VA; October 2015.
A modeling and simulation framework for exposure-response analysis in oncology: comparison and considerations of multiple methodologies
Polhamus D, French J, Chen S-C, Wang B, Li C, Lu D, Girish S, Jin J, Quartino A. Presented at the 6th American Conference on Pharmacometrics, Arlington, VA; October 2015.
Simulation from ODE-based population PK/PD and systems pharmacology models in R with mrgsolve
Baron KT and Gastonguay MR. Presented at the 6th American Conference on Pharmacometrics (ACoP), Arlington, VA; October 2015.
Linking a mechanistic model of bone mineral density to a time-to-event model of fracture
Eudy RF, Gillespie WR, Riggs MM, Gastonguay MR. Presented at the 6th American Conference on Pharmacometrics (ACoP), Arlington, VA; October 2015.
Trends in the application of pharmacometric modeling and simulation in the development of orphan drugs in the 21st century
Hajjar J, Fisher J, Gastonguay MR. Presented at the 6th American Conference on Pharmacometrics (ACoP), Arlington, VA; October 2015.
Implementing FDA specifications in R for submission of analysis datasets
Bergsma T and Pivirotto S. Presented at the 6th American Conference on Pharmacometrics (ACoP), Arlington, VA, October 2015.
Modeling & simulation: Filling the knowledge gap in rare diseases. Return on Investment on the Utilization of Systems Pharmacology and pharmacometrics in drug development for rare diseases: challenges and opportunities
Gastonguay MR and Godfrey CJ. American College of Clinical Pharmacology (ACCP) Workshop, September 26, 2015.
A priori identifiability of target-mediated drug disposition models and approximations
Eudy RJ, Riggs MM, Gastonguay MR. AAPS J. 2015 Sep;17(5):1280-4.
Assessment of propensity score and Mahalanobis distance matching in the exposure-response setting
Polhamus D, French J. Presented at the Annual Meeting of the Population Approach Group in Europe (PAGE), Hersonissos, Greece; June 2015.
Model-based meta-analysis for development of a population pharmacokinetic (PPK) model for vitamin D3 and its 25OHD3 metabolite
Ocampo-Pellend AS, Gastonguay, French JL, Riggs MM. Presented at the Annual Meeting of the Population Approach Group in Europe (PAGE), Hersonissos, Greece; June 2015.
FDA advisory meeting clinical pharmacology review utilizes a quantitative systems pharmacology (QSP) model: A watershed moment?
Peterson MC and Riggs MM. CPT: Pharmacometrics & Systems Pharmacology, 2015 Mar; 4(3).
Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop
Romero K, Sinha V, Allerheiligen S, Danhof M, Pinheiro J, Kruhlak N, Wang Y, Wang SJ, Sauer JM, Marier JF, Corrigan B, Rogers J, Lambers Heerspink HJ, Gumbo T, Vis P, Watkins P, Morrison T, Gillespie W, Gordon MF, Stephenson D, Hanna D, Pfister M, Lalonde R, Colatsky T. Journal of Pharmacokinetics and Pharmacodynamics, 2014 Dec;41(6):545-52. doi: 10.1007/s10928-014-9390-0.
Web-based software for real-time simulation-assisted trial design in Alzheimer’s disease
Polhamus DG, Kang J, Rogers JA, and Gastonguay MR. Presented at the 7th Annual Clinical Trials on Alzheimer’s Disease (CTAD), November 2014.
Establishing a priori identifiability of target mediated drug disposition models
Eudy RJ and Gastonguay MR. Presented at the 5th American Conference on Pharmacometrics (ACoP), Las Vegas, NV, October 2014.
Self-auditing data tables for R
Bergsma T and Pivirotto S. Presented at the 5th American Conference on Pharmacometrics (ACoP), Las Vegas, NV, October 2014.
Elastic cloud computing in pharmacometrics: Usage data and strategies for efficient workflows
Knebel W, Gastonguay M, Polhamus D, Hane JT. Presented at the Annual Meeting of the Population Analysis Group in Europe (PAGE), Alicante, Spain; June 2014; Abstract I-55.
Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations
J. S. Gewandter, R. H. Dworkin, D. C. Turk, M. P. McDermott, R. Baron, M. R. Gastonguay, I. Gilron, N. P. Katz, C. Mehta, S. N. Raja, S. Senn, C. Taylor, P. Cowan, P. Desjardins, R. Dimitrova, R. Dionne, J. T. Farrar, D. J. Hewitt, S. Iyengar, G. W. Jay, E. Kalso, R. D. Kerns, R. Leff, M. Leong, K. L. Petersen, B. M. Ravina, C. Rauschkolb, A. S. C. Rice, M. C. Rowbotham, C. Sampaio, S. H. Sindrup, J. W. Stauffer, I. Steigerwald, J. Stewart, J. Tobias, R.-D. Treede, M. Wallace, and R. E. White. Pain. 2014 Sep;155(9):1683-95. doi: 10.1016/j.pain.2014.05.025. Epub 2014 May 24.
A cloud-based cluster computing platform for pharmacometric applications
Bergsma T, Knebel W, Polhamus D, Hane JT, Gastonguay MR. Presented at the 4th American Conference on Pharmacometrics (ACoP), Ft. Lauderdale; May 2013.
Facilitating pharmacometric workflow with the metrumrg package for R
Bergsma TT, Knebel W, Fisher J, Gillespie WR, Riggs MM, Gibiansky L, Gastonguay MR. Comput Methods Programs Biomed. 2013 Jan;109(1):77-85.
Sumo: An authenticating web application with an embedded R session
Bergsma TT and Smith MS. The R Journal; June 2012, Vol. 4 Issue 1, p60-63.
From evidence synthesis to trial optimization: The adsim package for model-based simulation in Alzheimer’s disease
Polhamus D, Rogers JA, Gillespie W, French J, and Gastonguay M. Presented at the 21st Annual Meeting of the Population Approach Group Europe (PAGE), Venice, Italy, June 2012, Abstract 2580.
Building a scalable pharmacometrics platform in the cloud
Hane J and Kraut A. Presented at BioIT World Conference and Expo, Boston, MA; April 23-25, 2012.
The value of evidence synthesis: Model-based meta-analysis based on the CAMD database, the ADNI AD cohort data, and literature meta-data
Rogers JA, Polhamus D, Ito K, Qiu R, Gillespie W, Corrigan B. Presented at the 2012 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, National Harlbor, MD; March 2012.
Two guys and a credit card: Metrum’s Amazon cloud makeover – A case study in transferring a life sciences IT infrastructure fully into the cloud
Davies K. Bio-IT World, Feb 14, 2012.
Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: A review of methodology and 42 case studies
Gastonguay MR. Presented at the 20th Annual Meeting of the Population Approach Group Europe (PAGE), Athens, Greece, June 2011. Abstract 2229.
Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1) activity after oral administration of AMG 221, a selective 11β‐HSD1 inhibitor
Gibbs JP, Emery MG, McCaffery I, Smith B, Gibbs MA, Akrami A, Rossi J, Paweletz K, Gastonguay MR, Bautista E, Wang M, Perfetti R, Daniels O. J Clin Pharmacol. 51(6):830-41. June 2011.
Strategic data handling for pharmacometrics
Bergsma T. Presented at ACOP; April 2011; San Diego, CA.
Systematic review of versioned files for modeling and simulation quality control: the“review” R package
Bergsma T, Fisher J, Gastonguay MR, Hane J, Knebel W, Riggs MM, Rogers JA. Presented at ACOP; April 2011; San Diego, CA.
Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years
Knebel W, Tammara B, Udata C, Comer G, Gastonguay MR, Meng X. J Clin Pharmacol. 51(3):333-45. March 2011.
A longitudinal dose-response model for the progression of alzheimers disease, based on a combination of summary-level and patient-level data
Rogers JA, Ito K, Gillespie WR, Corrigan BW, Gastonguay MR. Presented at the Fourth Annual Bayesian Biostatistics Conference, Houston, TX. 26–28 January 2011.
Quantifying uncertainty in predictions of hepatic clearance
Rogers JA, Wilbur J, Cole S, Bernhardt PW, Bupp JL, Lennon MJ, Langholz N, Steiner CP. Statistics in Biopharmaceutical Research. 3(4):515-525. (2011)
Development of mechanistic/multiscale/systems biology models in clinical pharmacology and translational research: do the challenges outweigh the potential benefits?
Riggs MM. 2010 AAPS Clinical Pharmacology and Translational Research (CPTR) Open Forum; 16 November 2010.
Pharmacometrics as a discipline is entering the “industrialization” phase: standards, automation, knowledge sharing, and training are critical for future success
Romero K, Corrigan B, Tornoe CW, Gobburu JV, Danhof M, Gillespie WR, Gastonguay MR, Meibohm B, Derendorf H. J Clin Pharmacol. 50(9 Suppl):9S-19S. September 2010.
Defining the future of pharmacometrics: the American Society of Pharmacometrics
Pfister M, Brundage RC, Gastonguay MR, Miller R, Tannenbaum SJ, D’Argenio DZ. J Clin Pharmacol. ;50(9 Suppl):158S. September 2010.
ACoP: the tools, carpenters, and architects building the discipline of pharmacometrics
Brundage RC, Pfister M, D’Argenio DZ, Gastonguay MR, Miller R, Tannenbaum SJ. J Clin Pharmacol. 50(9 Suppl):7S-8S. September 2010.
Comparison of MCMC simulation results using NONMEM 7 or WinBUGS with BUGSModelLibrary
Gastonguay MR, Gillespie WR, Bauer RJ. Presented at PAGE 2010. Berlin, Germany. 8–11 June 2010
Utilizing NONMEM 7 and the intel fortran compiler in a distributed computing environment
Knebel W, Bergsma TT, Dagdigian C, Hane J, Gastonguay MR. Presented at PAGE 2010, 19th Meeting, Berlin, Germany, June 8–11, 2010.
Predicting nonlinear changes in BMD over time using a physiologically-based mathematical model
Peterson MC and Riggs MM. Presented at American Association of Pharmaceutical Scientists National Biotechnology Conference, Update on Quantitative Systems and Disease Models for Biologics. Mini–Symposium. San Francisco, CA; May 2010.
Population pharmacokinetics of dexmedetomidine in infants after open heart surgery
Su F, Nicolson SC, Gastonguay MR, Barrett JS, Adamson PC, Kang DS, Godinez RI, Zuppa AF. Anesth Analg. 110(5):1383-92. May 2010.
Multiscale modeling: the quantitative integration of systems biology, clinical pharmacology and translational research
Riggs MM. Presented at American Association of Pharmaceutical Scientists National Biotechnology Conference, Update on Quantitative Systems and Disease Models for Biologics. Mini–Symposium. San Francisco, CA; May 2010.
An issue in controlling the type 1 error rate with adaptive designs using time-to-event endpoints
Rogers JA. Presented at 3rd Annual FDA/MTLI Medical Device and IVD Statistics Workshop. 28 April 2010.
Comparative performance of bayesian markov chain monte carlo and maximum likelihood population estimation methods when applied to nonlinear pharmacokinetics of monoclonal antibodies
Dirks N, Gastonguay MR, Gillespie WR, Knebel W, Riggs MM, Panetta JC, and Meibohm B. Presented at ASCPT 111th Annual Meeting, March 17-20, 2010.
Exposure-response modeling and clinical trial simulation of the effect of tolterodine on QT intervals in healthy volunteers
Sweeney KR, Gastonguay MR, Benincosa L, Cronenberger CL, Glue P, Malhotra BK. Drug Discov Ther. 4(1):44-53. February 2010.
Quantitative assessment of exposure–response relationships for the efficacy and tolerability of varenicline for smoking cessation
Ravva JP, Gastonguay MR, French JL, Tensfeldt TG, and Faessel HM. Clinical Pharmacology & Therapeutics. 87(3):336-44. January 2010.
Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months
Mondick JT, Johnson BM, Haberer LJ, Sale ME, Adamson PC, Coté CJ, Croop JM, Russo MW, Barrett JS, Hoke JF. Eur J Clin Pharmacol. 66(1):77-86. January 2010.
The impact of missing data on model evaluation
Gastonguay MR. Presented at ACOP 2009. 6 October 2009; Mashantucket, CT.
Population dose-response model for ADAS-cog ccores in patients with alzheimers disease by meta-analysis of a mixture of summary and individual data
Gillespie WR, Rogers JA, Ito K, Gastonguay MR. Presented at ACOP 2009. October 4-7, 2009; Mashantucket, CT.
Prototype model library for bayesian pharmacokinetic/pharmacodynamic (PKPD) modeling in WinBUGS
Gillespie B, Gastonguay MR. Presented at ACOP 2009. October 4-7, 2009; Mashantucket, CT.
A systems biology model to describe long-term bone remodeling effects of estrogen in menopausal and postmenopausal women
Riggs MM, Peterson MC, Gastonguay MR. Presented at ACOP 2009. October 4-7, 2009; Mashantucket, CT.
Preliminary population pharmacokinetic modeling of PF-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate alzheimer’s disease
Nicholas T, Knebel W, Gastonguay MR, Bednar MM, Billing B, Landen JW, Kupiec JW, Corrigan B, Laurencot R, Zhao Q. Poster presented at the ICAD 2009 Annual Meeting; July 11–16, 2009; Vienna, Austria.
Population dose-response model for ADAS-cog scores in patients with alzheimer’s disease by meta-analysis of a mixture of summary and individual data
Gillespie B, Rogers JA, Ito K, Gastonguay MR. ASCPT 110th Annual Meeting, March 18-21, 2009; Washington D.C.
Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease
Knebel W, Palmen M, Dowell JA, Gastonguay M. J Clin Pharmacol. 48(7):837-48. July 2008.
Population pharmacokinetic modeling of fosamprenavir in pediatric HIV-infected patients
Fisher J, Gastonguay MR, Knebel W, Gibiansky L, Wire MB. Poster presented at the American Conference on Pharmacometrics. March 9-12 2008; Tucson, Arizona.
Use of rpad, an open-source, interactive, web-based analysis program, for visualization during model-based drug development of adipiplon, a GABAA receptor partial agonist under investigation for the treatment of insomnia
Riggs MM, Bergsma TT, Gillespie WR, Gastonguay MR, Sprenger KJ. Poster presented at the American Conference on Pharmacometrics. March 9-12 2008; Tucson, Arizona.
Open source software tools for parallel computation of multiple MCMC chains with WinBUGS
Gillespie WR, Gastonguay MR, Knebel W, Georgalis G. Poster presented at the American Conference on Pharmacometrics. March 9-12 2008; Tucson, Arizona.
Facilitating the pharmacometrics work-flow with the mItools r package
Knebel W, Bergsma T, Fisher J, Georgalis G, Gibiansky L, Gillespie WR, Riggs MM, Gastonguay MR. Poster presented at the American Conference on Pharmacometrics. March 9-12 2008; Tucson, Arizona.
Bayesian approaches to mixed effects models for ordered categorical data
Gillespie WR, Gastonguay MR, Knebel W. Presented at the AAPS Annual Meeting; November 2007; San Diego, CA.
Population pharmacokinetic-pharmacodynamic modeling of istradefylline in patients with parkinson’s disease
Knebel W, Rao N, Bergsma T, Gastonguay M, Mori A, Uchimura T, Allenby K, Dvorchik B, Sussman N, Chaikin P. Presented at ACCP; October 14-17, 2007; Denver, CO.
Quantitative assessment of exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation
Rawa P, Faessel H, Gastonguay MR, Tensfeldt TG, Reeves K. Clin Pharmacol Ther. 81(S1) March 2007; Abstract PII-73: S72.
Exposure-response (PK-PD) applied to model-based drug development: A case study of drug x
Riggs M. FDA/Industry Statistics Workshop. 29 September 2006; Washington D.C.; Parallel Session 14: Case Studies in Modeling and Simulation, Abstract.
Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy
Agoram B, Heatherington AC, Gastonguay MR. AAPS Journal. 8(3), September 2006. doi: 10.1208/aapsj080364
Acknowledging and incorporating uncertainty in model-based inferences
Gastonguay MR, Gibiansky L. Presented at the ECPAG Conference. July 24-26, 2006; Rockville, MD; Workshop Poster Session, Abstract.
Acknowledging parameter uncertainty in the simulation-based design of an actinomycin-D pharmacokinetic study in pediatric patients with Wilms’ Tumor or rhabdomyosarcoma
Mondick JT, Gibiansky L, Gastonguay MR, Veal GJ, Barrett JS. Presented at PAGE 2006. June 14-16, 2006; Brugge/Bruges, Belgium; Abstract 938.
R/NONMEM Toolbox for simulation from posterior parameter (uncertainty) distributions
Gibiansky L and MR Gastonguay. Presented at PAGE 2006. June 14-16, 2006; Brugge/Bruges, Belgium; Abstract 958.
Acknowledging parameter uncertainty by simulating from posterior distributions with NONMEM and R
Gastonguay MR, Gibiansky L. Presented at the MUFPADA Annual Meeting. May 2-3, 2006; Ann Arbor, MI; Abstract.
NMQual: A tool to automate installation and facilitate qualification of NONMEM
Knebel B, Bergsma T, Gibiansky L, Hane JT, Gastonguay MR. Presented at PAGE Annual Meeting. June 16-17, 2005; Pamplona, Spain; Abstract 779.
Modeling and simulation guided design of a pediatric population pharmacokinetic trial for hydromorphone
Gastonguay MR, El-Tahtawy A. The AAPS Journal. 7(S2), June 2005. Abstract W5318.
Effect of NONMEM minimization status and number of replicates on bootstrap parameter distributions for population pharmacokinetic models: a case study
Gastonguay MR, El-Tahtawy A. Clinical Pharmacology and Therapeutics. 77(2), P2-P2; February 5, 2005.
Population pharmacokinetic model of sedative doses of GPI 15715 and propofol liberated from GPI15715
Gibiansky E, Gibiansky L, Enriquez J. Clinical Pharmacology and Therapeutics. 77(2), P48-P48; February 5, 2005.
NONMEM Non-influential correlated ETAs bug and how to fix it
Gibiansky L. Presented at AAPS Annual Meeting: PPDM Poster-Podium Session, November 10, 2004; Baltimore, MD.
Estimation and prediction of chaotic pharmacodynamic systems using nonlinear mixed-effects models: the butterfly effect
Gastonguay MR, Bies R. The AAPS Journal. 6(S1) (2004); Abstract W4353, 2004.